Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-01

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371

Platelet Aggregation

TERMINATED PHASE4

Platelet Inhibition by Aspirin, Acetaminophen and NSAID

NCT00536068

Hemostasis

COMPLETED NA

Duration of Platelet Inhibition by Aspirin

NCT00671021

Coronary Artery Disease

COMPLETED

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

NCT02243137

Adverse Effect of Antithrombotic Drugs

COMPLETED PHASE1

Aspirin Dosing in Diabetic Patients

NCT01201785

Type 2 Diabetes Mellitus Coronary Artery Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Dysfunction Due to Aspirin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin supplemented

Group Type EXPERIMENTAL

Aspirin

Intervention Type DRUG

1 week of aspirin supplementation prior to sampling

Off aspirin

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspirin

1 week of aspirin supplementation prior to sampling

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use.
* Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin.
* Willingness to repeat this process after two months and four months of the initial sampling date.